FRIEDREICH ATAXIA- STEROIDOGENESIS (FRIEDSTERO)

Istanbul University

Status: Enrolling

Conditions: Friedreich's Ataxia; Steroidogenesis

Study type: Observational

Funder types: Other

Identifiers

NCT07123142

ITF_FERREDOX

CEDD2025_FAS_Study (Other Identifier)

Details and patient eligibility

About

Friedreich's ataxia (FA) is a rare autosomal recessive disorder caused by GAA repeat expansion in the FXN gene, leading to impaired iron-sulfur (Fe-S) cluster biosynthesis and mitochondrial dysfunction. Fe-S clusters are essential for the function of several enzymes involved in steroid hormone production. While animal and cell culture studies suggest impaired steroidogenesis in FA, no clinical study has systematically evaluated this in human patients. This pilot study aims to investigate adrenal and gonadal steroidogenesis pathways in FA patients using LC-MS/MS-based steroid profiling. A total of 11 genetically confirmed FA patients followed at Istanbul Faculty of Medicine will be enrolled. Clinical data and serum samples will be collected and compared with those of 15 age- and sex-matched healthy controls. The findings are expected to enhance understanding of endocrine alterations in FA and guide future therapeutic approaches.

Full description

Friedreich's ataxia (FA) is characterized by mitochondrial dysfunction due to impaired iron-sulfur (Fe-S) cluster formation caused by GAA repeat expansion in the FXN gene. Fe-S clusters are crucial for the activity of several mitochondrial enzymes, including cytochrome P450 family members such as CYP11A1, CYP11B1, and CYP11B2, which are involved in the biosynthesis of steroid hormones. These enzymes require ferredoxin and ferredoxin reductase, whose function also depends on Fe-S clusters. Experimental studies have shown reduced levels of testosterone and progesterone in FA models, suggesting that steroidogenesis is disrupted in FA. This study will evaluate the steroid profiles of FA patients via LC-MS/MS, compare them with healthy controls, and investigate correlations with age, sex, and disease severity. It will be the first clinical study to address steroidogenic defects in FA patients.

Enrollment: 25 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria (FA Group):

• Genetically confirmed Friedreich's Ataxia diagnosis
• Signed informed consent (parents and/or participants depending on age)

Inclusion Criteria (Control Group):

• Healthy individuals with no known chronic or endocrine disease
• Age- and sex-matched to FA patients
• Signed informed consent

Trial design

25 participants in 2 patient groups

Friedreich's ataxia group

Description:

Genetically confirmed FA

Healthy Control Group

Description:

not having any known disease and being similar age, sex and pubertal status with the disease group